Eternity in Medical Information -- Medisurf
Search | Web Directory, News, Variable useful Information, PubMed In Medine, All
Category Select :
Items 21 ~ 40 of 25713, Page 2 of 1287
21. Survivor Faces Endometrial Cancer Diagnosis With Strength and Hope
When she learned she had endometrial cancer, Tina Silas says she cried, but not for long. “I had my 5 minutes of emotion, and then I moved forward,” said Silas.
12/24/2018 American Cancer Society
22. Year in Review: Cancer Research Insights from 2018
Read highlights about American Cancer Society research from 2018.
12/22/2018 American Cancer Society
23. 2018 in Review: CDC Looks Back at the Year’s Most Pressing Health Threats
From the opioid overdose epidemic to foodborne disease outbreaks and antimicrobial resistance to the Ebola virus outbreak in the Democratic Republic of Congo (DRC), CDC worked around the clock ? and around the globe ? to protect Americans from health threats in 2018.
12/21/2018 Centers for Disease Control and Prevention
24. FDA permits marketing of a diagnostic test to aid in measuring nutrients in breast milk
Miris Human Milk Analyzer, a new diagnostic test to aid healthcare professionals in measuring nutrients in breast milk, including the concentration of fat, carbohydrate, protein, total solids and energy
12/21/2018 U.S. FOOD & DRUG ADMINISTRATION
25. New Data Show Growing Complexity of Drug Overdose Deaths in America
In-depth analysis confirms sharp increases, geographic spread of synthetic opioid-related deaths
12/21/2018 Centers for Disease Control and Prevention
26. FDA approves first treatment for rare blood disease
Elzonris (tagraxofusp-erzs) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients, two years of age and older
12/21/2018 U.S. FOOD & DRUG ADMINISTRATION
27. FDA approves new treatment for adult patients with rare, life-threatening blood disease
Ultomiris (ravulizumab) injection for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disease
12/21/2018 U.S. FOOD & DRUG ADMINISTRATION
28. FDA sends warning to company for marketing dangerous unapproved stem cell products that put patients at risk and puts other stem cell firms, providers on notice
Genetech, Inc. warned about umbilical cord blood-derived cellular products distributed by Liveyon, LLC. FDA is also sending letters to other firms and providers offering stem cell treatments notifying them of agency’s regenerative medicine policy framework.
12/20/2018 U.S. FOOD & DRUG ADMINISTRATION
29. Deadly Marburg Virus Found in Sierra Leone Bats
First time this Ebola-like virus identified in West Africa
12/20/2018 Centers for Disease Control and Prevention
30. FDA warns about safety risks of teething necklaces, bracelets to relieve teething pain or to provide sensory stimulation
12/20/2018 U.S. FOOD & DRUG ADMINISTRATION
31. Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps to strengthen the long-term safety oversight of the Essure device following discontinuation of its U.S. sales
FDA continues to evaluate the product’s long-term safety profile past its scheduled discontinuation from the U.S. market following a series of earlier regulatory actions that we took apply significant new requirements on its use. This includes the agency’s decision to take the step of making Essure a restricted device
12/20/2018 U.S. FOOD & DRUG ADMINISTRATION
32. LYNPARZA® (olaparib) Meets Primary Endpoint in Phase 3 SOLO-3 Trial for the Treatment of Relapsed BRCA-Mutated Advanced Ovarian Cancer
AstraZeneca and Merck’s LYNPARZA Significantly Improved Objective Response Rate Compared to Chemotherapy in Platinum-Sensitive Relapsed Patients Who Had Two or More Prior Lines of Chemotherapy
12/20/2018 MERCK
33. Statement from FDA Commissioner Scott Gottlieb, M.D., on signing of the Agriculture Improvement Act and the agency’s regulation of products containing cannabis and cannabis-derived compounds
12/20/2018 U.S. FOOD & DRUG ADMINISTRATION
34. Merck Provides Update on KEYTRUDA® (pembrolizumab) Supplemental Biologics License Application (sBLA) for KEYNOTE-042 Trial
Merck’s anti-PD-1 therapy, as monotherapy for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients whose tumors express PD-L1 (tumor proportion score [TPS] ≥1%) without EGFR or ALK genomic tumor aberrations
12/20/2018 MERCK
35. New Study Finds Higher than Expected Number of Suicide Deaths among U.S. Veterinarians
Female veterinarians at particularly high suicide risk
12/20/2018 Centers for Disease Control and Prevention
36. LYNPARZA® (olaparib) Approved by FDA for First-Line Maintenance Therapy in BRCA-Mutated Advanced Ovarian Cancer
AstraZeneca and Merck’s LYNPARZA Reduced the Risk of Disease Progression or Death by 70 Percent Compared to Placebo Following Response to Platinum-Based Chemotherapy / First PARP Inhibitor Approved in First-Line Maintenance for BRCAm Advanced Ovarian Cancer
12/19/2018 MERCK
37. Almost 4% of Cancers Worldwide Due to Excess Body Weight
Excess body weight is responsible for an estimated 544,300 cancers, which is about 3.9% of all cancers in the world, according to research by the American Cancer Society, Imperial College London, and the Harvard T.H. Chan School of Public Health.
12/19/2018 American Cancer Society
38. Medtronic Completes Acquisition of Mazor Robotics
Company Integrates Robotics and Aims to Make Spine Surgery More Predictable and Transform Outcomes for Hospitals, Surgeons, and Patients
12/19/2018 Medtronic
39. FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Adult and Pediatric Patients with Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma, a Rare Form of Skin Cancer
Accelerated Approval Based on Results of CITN-09/KEYNOTE-017, Where KEYTRUDA Monotherapy Demonstrated an Objective Response Rate of 56 percent
12/19/2018 MERCK
40. Get Bubbly this New Year with Abbott''s New Pedialyte® Sparkling Rush™ Powder Packs
Pedialyte Sparkling Rush is advanced rehydration with a fizz, with an optimal balance of electrolytes and carbohydrate to prevent mild to moderate dehydration
12/19/2018 Abbott
   
1 2 3 4 5 6 7 8 9 10
 
경기도 성남시 분당구 구미동 25-1 엘레강스 프라자 ㈜ 메디서프 | Tel : 031-896-0930 | 사업자 등록번호 : 212-81-47247
통신판매신호번호 : 경기 성남 2007-712 | 대표이사 한상욱